Product introduction:
Clindamycin HCl is a semi synthetic antibiotic with broad antibacterial spectrum and strong antibacterial activity. It has obvious antibacterial activity against Gram-positive bacteria and can effectively kill Staphylococcus, anaerobic bacteria, pneumococcus and Streptococcus. It has active effects on pathogenic parasites such as Pneumocystis, Toxoplasma gondii and Plasmodium falciparum, and has little adverse reactions. At present, clindamycin products used in clinic include clindamycin hydrochloride, clindamycin phosphate and clindamycin palmitate. Clindamycin phosphate and clindamycin palmitate have no antibacterial activity and play an antibacterial and anti parasite role after they are metabolized into clindamycin in vivo. Clindamycin hydrochloride is a derivative of lincomycin. The antibacterial spectrum of clindamycin hydrochloride is wider than lincomycin, and the antibacterial activity is 4-8 times higher than lincomycin. It has antibacterial activity against gram-positive aerobic bacteria, Staphylococcus and Streptococcus, and also has antibacterial activity against Mycoplasma, chlamydia and a variety of anaerobic bacteria.
CAS:21462-39-5
Structural type:
Molecular formula: C18H34Cl2N2O5S
Molecular weight: 461.44
Uses: antibiotics; Clindamycin hydrochloride is a lincomycin derivative. Its bactericidal activity against Staphylococcus aureus and pneumococcus is many times stronger than lincomycin.